(Q43636701)

25 November 2017

Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol (English)

1 reference

25 November 2017

1 reference

Bron AM

1

1 reference

25 November 2017

Denis P

2

1 reference

25 November 2017

Nordmann JP

3

1 reference

25 November 2017

Rouland JF

4

1 reference

25 November 2017

Sellem E

5

1 reference

25 November 2017

Johansson M

6

1 reference

25 November 2017

1 June 2001

1 reference

25 November 2017

1 reference

25 November 2017

79

1 reference

25 November 2017

3

1 reference

25 November 2017

289-293

1 reference

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

25 November 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

Long-Term Experience with Timolol Ophthalmic Solution in Patients with Open-Angle Glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

The effect of adding prostaglandin F2 alpha-isopropylester to timolol in patients with open angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

7 January 2021

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

7 January 2021

The effects of withdrawal of timolol in chronically treated glaucoma patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

7 January 2021

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

7 January 2021

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790316.X

7 January 2021

10.1034/J.1600-0420.2001.790316.X

Identifiers

DOI

1 reference

25 November 2017

1 reference